JP2019513762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513762A5 JP2019513762A5 JP2018553113A JP2018553113A JP2019513762A5 JP 2019513762 A5 JP2019513762 A5 JP 2019513762A5 JP 2018553113 A JP2018553113 A JP 2018553113A JP 2018553113 A JP2018553113 A JP 2018553113A JP 2019513762 A5 JP2019513762 A5 JP 2019513762A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- fibrosis
- phenyl
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 230000004761 fibrosis Effects 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- -1 2-[(5-nitro-1,3-thiazol-2-yl) carbamoyl] phenyl Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 125000004431 deuterium atom Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 230000003176 fibrotic effect Effects 0.000 claims 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 208000003167 cholangitis Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000007942 carboxylates Chemical group 0.000 claims 3
- 230000001587 cholestatic effect Effects 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 210000000936 intestine Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- 102000005862 Angiotensin II Human genes 0.000 claims 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims 2
- 206010008635 Cholestasis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 229950006323 angiotensin ii Drugs 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 230000007870 cholestasis Effects 0.000 claims 2
- 231100000359 cholestasis Toxicity 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000004872 soft tissue Anatomy 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- ARERRRAWYXBDEE-UHFFFAOYSA-N 2,6-difluoro-n-(5-methyl-4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C=2C=CC=CC=2)=C(C)SC=1NC(=O)C1=C(F)C=CC=C1F ARERRRAWYXBDEE-UHFFFAOYSA-N 0.000 claims 1
- GJHKVYZSTJDPHJ-UHFFFAOYSA-N 2-[2-(1,3-benzothiazol-2-ylcarbamoyl)phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1C(=O)NC1=NC2=CC=CC=C2S1 GJHKVYZSTJDPHJ-UHFFFAOYSA-N 0.000 claims 1
- DVPZNDXXOYUTHA-UHFFFAOYSA-N 2-chloro-n-(4-naphthalen-2-yl-1,3-thiazol-2-yl)-5-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C(=O)NC=2SC=C(N=2)C=2C=C3C=CC=CC3=CC=2)=C1 DVPZNDXXOYUTHA-UHFFFAOYSA-N 0.000 claims 1
- YBGBTGGBNZEUJS-UHFFFAOYSA-N 5-chloro-1,3-thiazole Chemical compound ClC1=CN=CS1 YBGBTGGBNZEUJS-UHFFFAOYSA-N 0.000 claims 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 1
- 108010059616 Activins Proteins 0.000 claims 1
- 201000011374 Alagille syndrome Diseases 0.000 claims 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010056375 Bile duct obstruction Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims 1
- 102100031168 CCN family member 2 Human genes 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 1
- 108091006109 GTPases Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 1
- 108010004250 Inhibins Proteins 0.000 claims 1
- 102000002746 Inhibins Human genes 0.000 claims 1
- 108010005239 Inhibitory Smad Proteins Proteins 0.000 claims 1
- 102000005856 Inhibitory Smad Proteins Human genes 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 claims 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010034464 Periarthritis Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims 1
- 208000012619 Progressive familial intrahepatic cholestasis type 3 Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims 1
- 101710084191 TGF-beta receptor type-1 Proteins 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000868 anti-mullerian hormone Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 201000005271 biliary atresia Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims 1
- 208000019298 familial intrahepatic cholestasis Diseases 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 150000002224 folic acids Chemical class 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000007897 gelcap Substances 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000893 inhibin Substances 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims 1
- 230000007872 intrahepatic cholestasis Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 210000001370 mediastinum Anatomy 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 claims 1
- OIBTYFAIDUIJEK-UHFFFAOYSA-N n-(5-benzamido-4-thiophen-2-yl-1,3-thiazol-2-yl)-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NC(S1)=NC(C=2SC=CC=2)=C1NC(=O)C1=CC=CC=C1 OIBTYFAIDUIJEK-UHFFFAOYSA-N 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 235000016236 parenteral nutrition Nutrition 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- QKHIVXQAPKMQRV-UHFFFAOYSA-N phenyl 2-amino-3-methylpentanoate Chemical compound CCC(C)C(N)C(=O)OC1=CC=CC=C1 QKHIVXQAPKMQRV-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical group C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002148 progressive familial intrahepatic cholestasis 3 Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 210000000574 retroperitoneal space Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 230000008410 smoothened signaling pathway Effects 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000003375 sulfoxide group Chemical group 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 108091008743 testicular receptors 4 Proteins 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 0 CC=*[C@@](*)(C(F)(F)F)C(C)=O Chemical compound CC=*[C@@](*)(C(F)(F)F)C(C)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305426 | 2016-04-11 | ||
| EP16305426.5 | 2016-04-11 | ||
| EP16305428.1 | 2016-04-11 | ||
| EP16305428 | 2016-04-11 | ||
| PCT/EP2017/055881 WO2017178174A1 (en) | 2016-04-11 | 2017-03-13 | Methods of treatment of cholestasis and fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513762A JP2019513762A (ja) | 2019-05-30 |
| JP2019513762A5 true JP2019513762A5 (https=) | 2020-04-02 |
Family
ID=58261675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553113A Pending JP2019513762A (ja) | 2016-04-11 | 2017-03-13 | 胆汁うっ滞及び線維症の処置方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170290814A1 (https=) |
| EP (1) | EP3442952A1 (https=) |
| JP (1) | JP2019513762A (https=) |
| WO (1) | WO2017178174A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191466A1 (ru) | 2016-04-11 | 2021-12-31 | Женфит | Способы лечения холестатических и фибротических заболеваний |
| KR20190122806A (ko) * | 2017-03-13 | 2019-10-30 | 장피트 | 조합 치료요법용 약학 조성물 |
| CN110575540B (zh) * | 2018-06-07 | 2021-11-02 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
| CN113677336B (zh) | 2019-04-10 | 2024-04-30 | 基恩菲特公司 | 包含式(i)化合物和glp-1受体激动剂的组合疗法 |
| CA3130518A1 (en) * | 2019-04-12 | 2020-10-15 | Nicolas STANKOVIC-VALENTIN | Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress |
| CN112480104B (zh) * | 2019-09-11 | 2024-06-18 | 绍兴君科臻元医药科技有限公司 | 硝唑尼特衍生物及其医药用途 |
| CA3179059A1 (en) * | 2020-06-09 | 2021-12-16 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| CN116077502B (zh) * | 2021-11-05 | 2025-12-23 | 广州医科大学附属妇女儿童医疗中心 | 叶酸在预防、诊断和治疗胆道闭锁中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
| EP1354603A1 (en) * | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| RU2006111093A (ru) * | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| US20050130974A1 (en) * | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| AU2006343359A1 (en) * | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| US20100056505A1 (en) * | 2005-11-21 | 2010-03-04 | Biogen Idec Ma Inc. | Substituted Pyrazalones |
| AP2907A (en) * | 2006-01-09 | 2014-05-31 | Romark Lab Lc | Viral hepatitis treatment |
| CA2639910A1 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| EP2609095A4 (en) * | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| US9856240B2 (en) * | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2014059333A1 (en) * | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN107105660A (zh) * | 2014-11-11 | 2017-08-29 | 罗马克实验室有限公司 | 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法 |
| US20190070154A1 (en) * | 2015-06-24 | 2019-03-07 | Duke University | New methods of use for an anti-diarrhea agent |
| EA202191466A1 (ru) * | 2016-04-11 | 2021-12-31 | Женфит | Способы лечения холестатических и фибротических заболеваний |
| SG11201906041QA (en) * | 2017-01-27 | 2019-08-27 | Genfit | Pharmaceutical compositions for combination therapy |
-
2017
- 2017-03-13 WO PCT/EP2017/055881 patent/WO2017178174A1/en not_active Ceased
- 2017-03-13 JP JP2018553113A patent/JP2019513762A/ja active Pending
- 2017-03-13 EP EP17709463.8A patent/EP3442952A1/en not_active Withdrawn
- 2017-03-13 US US15/457,538 patent/US20170290814A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513762A5 (https=) | ||
| JP2019513761A5 (https=) | ||
| JP2016528276A (ja) | プラーク退縮を促進するための組成物及び治療法 | |
| JP2011529037A5 (https=) | ||
| JP2019509288A5 (https=) | ||
| Zhong et al. | Understanding the molecular properties and metabolism of top prescribed drugs | |
| HRP20251042T1 (hr) | Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild) | |
| JP2008518999A5 (https=) | ||
| JP2008508360A5 (https=) | ||
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| JP2010511626A5 (https=) | ||
| MX377387B (es) | Nuevo compuesto para usarse en el tratamiento de fibrosis quística. | |
| JP2011521938A5 (https=) | ||
| JP2006514611A5 (https=) | ||
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| WO2002004449A2 (en) | Methods for treatment of conditions affected by activity of multidrug transporters | |
| JP2006508953A5 (https=) | ||
| JP2011500621A5 (https=) | ||
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| US20180311236A1 (en) | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease | |
| US20170290814A1 (en) | Methods of treatment of cholestasis and fibrosis | |
| AR054445A1 (es) | Formulaciones de un inhibidor de src/abl | |
| MX2024004438A (es) | Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes. | |
| JP2019516707A5 (https=) |